SCA
ABBV icon

Strathmore Capital Advisors’s AbbVie ABBV Stock Holding History

Strathmore Capital Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$784K Buy
3,946
+143
+4% +$31.7K 0.22% 67
2025
Q4 		$869K Sell
3,803
-115
-3% -$26.2K 0.28% 45
2025
Q3 		$907K Sell
3,918
-132
-3% -$26.9K 0.37% 39
2025
Q2 		$772K Buy
+4,050
New +$753K 0.34% 42

Other funds holding ABBV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Strathmore Capital Advisors's ABBV Position: Q1 2026 in Review

Strathmore Capital Advisors increased its AbbVie (ABBV) stake by 3.8% in Q1 2026, buying an estimated $31.7K and bringing the position to 3,946 shares worth $784K. The position accounts for 0.22% of the portfolio, ranked #67.

Strathmore Capital Advisors first reported a position in ABBV in Q2 2025 and has held it in 4 quarters since. The position peaked at $907K in Q3 2025. 4,076 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Strathmore Capital Advisors held 3,946 shares of AbbVie worth $784K as of Q1 2026.
  • Strathmore Capital Advisors bought 143 AbbVie shares in Q1 2026, an estimated $31.7K.
  • AbbVie made up 0.22% of Strathmore Capital Advisors's portfolio in Q1 2026, its #67 holding.
  • Strathmore Capital Advisors first reported a position in AbbVie in Q2 2025 and has held it in 4 quarters since.
  • Strathmore Capital Advisors's AbbVie position peaked at $907K in Q3 2025.
  • 4,076 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Strathmore Capital Advisors's 13F filing for Q1 2026, filed 27 Apr 2026.